We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Blood Test Determines Irritable Bowel Syndrome

By LabMedica International staff writers
Posted on 21 Nov 2013
Print article
Image: Micrograph of cryptitis in a case of Inflammatory Bowel Disease from a colonic biopsy of the mucosa (Photo courtesy of Nephron).
Image: Micrograph of cryptitis in a case of Inflammatory Bowel Disease from a colonic biopsy of the mucosa (Photo courtesy of Nephron).
A blood test could easily determine whether a patient is suffering from Irritable Bowel Syndrome (IBS), eliminating the need for extensive and expensive dialogistic testing in order to rule out more serious conditions like Inflammatory Bowel Disease (IBD).

Vinculin is a cell migration and adherence protein found predominantly on nerves and epithelium and a series of studies suggests that acute gastroenteritis causes antibodies to be formed to vinculin and is associated with IBS development.

Scientists at the Cedars Sinai Medical Center (Los Angeles, CA, USA) evaluated 165 IBS, 30 IBD and 26 healthy control subjects and demographics were similar between groups. The IBS subjects were aged between 18 and 65 and were all positive according to the Rome criteria. Subjects with IBD were recruited from an expert tertiary care medical center.

Overall, IBS had a significantly greater optical density in the enzyme-linked immunoassay (ELISA) for anti-vinculin antibodies compared to IBD and healthy subjects. The results from Cedars Sinai Medical Center were compared to those at Beth Israel Deaconess Medical Center (Boston, MA, USA) for IBS recruitment, and the findings from both centers were similarly abnormal. Interestingly, subjects with a history of acute gastroenteritis, even higher levels of antibodies were seen.

Mark Pimentel, MD, the lead author of this multicenter study, said, “Anti-vinculin antibodies are elevated in IBS compared to non-IBS. This is the first diagnostic test for IBS based on serum and a pathophysiologic mechanism of IBS through acute gastroenteritis precipitating molecular mimicry and autoimmunity. This is a major breakthrough as the first test to potentially distinguish IBS from IBD and reduce the need for unnecessary testing in these conditions. Moreover, this test is based on a potential pathophysiologic mechanism of IBS development.”

In the USA, it is estimated that 10%–15% of the adult population suffers from IBS symptoms, yet only 5%–7% of adults have been diagnosed with the disease. IBS is the most common disease diagnosed by gastroenterologists and one of the most common disorders seen by primary care physicians. The study was presented at 78th Annual Scientific Meeting of the American College of Gastroenterology, held October 11-16, 2013, in San Diego (CA, USA).

Related Links:

Cedars Sinai Medical Center
Beth Israel Deaconess Medical Center 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Pipet Controller
Stripettor Pro

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.